Eton Pharmaceuticals, Inc. ETON Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction at other companies
Other financials
Where this comes from
Reported directly by Eton Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction.
The official record: Eton Pharmaceuticals, Inc.’s 10-K, filed March 19, 2026, on SEC EDGAR. View the filing →
Ask your AI about Eton Pharmaceuticals, Inc.'s debt issuance costs incurred during noncash or partial noncash transaction.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Eton Pharmaceuticals, Inc.'s debt issuance costs incurred during noncash or partial noncash transaction?
- Eton Pharmaceuticals, Inc. (ETON) reported debt issuance costs incurred during noncash or partial noncash transaction of $0 in Q4 2025.
- How has Eton Pharmaceuticals, Inc.'s debt issuance costs incurred during noncash or partial noncash transaction changed year-over-year?
- Eton Pharmaceuticals, Inc.'s debt issuance costs incurred during noncash or partial noncash transaction decreased by 100.0% year-over-year, from $96.5K to $0.
- What does debt issuance costs incurred during noncash or partial noncash transaction mean?
- Records the non-cash costs associated with securing financing, such as legal, accounting, and underwriting fees that are settled through non-cash means or capitalized as part of a transaction. This metric highlights the friction costs of capital raising and debt restructuring. It is important for assessing the total cost of financing beyond simple interest payments.